| Market Cap | 43.45K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -96.99M |
| Shares Out | 434.51M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,000 |
| Average Volume | 14,674 |
| Open | 0.0001 |
| Previous Close | 0.0000 |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | 0.0000 - 0.0001 |
| Beta | 3.52 |
| RSI | 33.68 |
| Earnings Date | n/a |
About NUNZ
Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute Nunzia, a nutraceutical that treats autism, fragile X, ADHD, PTSD, and other disorders. It offers its products through wholesalers, as well as through its website nunziapharma.com. The company was formerly known as Arizona Gold and Onyx Mining Company and changed its name to Nunzia Pharmaceutical Company in February 2018. Nunzia Pharmaceutical Company was incorporated in 1986 and is based in Lon... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Nunzia Pharmaceutical Corporation (OTC: NUNZ), an Emerging Leader in Innovative Pharmaceutical and Nutraceuticals, is Now Offering a Patented Blood Warmer Through Nunzia's Medical Supply Division. 8K Filed 08/05/2021
LONG BEACH, CA, Aug. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Nunzia Pharmaceutical Corporation (OTC: NUNZ), an Emerging Leader in Innovative Pharmaceutical and Nutraceuticals, is now offering ...